Logo

Medicyte Licenses Life Technologies' Lentiviral Vector Technology

Mar 27, 2013 | staff reporter

NEW YORK (GenomeWeb News) – German firm Medicyte today said that it has licensed lentiviral vector technology from Life Technologies for use in developing cell-based assays.

Medicyte said that it would incorporate the licensed technology into its Upcyte cell products for the biopharma and academic research markets. Financial and other terms of the alliance were not disclosed.

"With the technology we have licensed from Life Technologies, we are capable to bring more predictive, reliable, and standardized cell strains on the market," Medicyte CEO Joris Braspenning said in a statement.

Medicyte's Upcyte technology is used to proliferate primary cells, which are used in cell-based assays for research, screening, and drug development.

Filed under

licensing agreement
cell-based assays
Thermo Fisher Scientific
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.